Results 41 to 50 of about 126,887 (307)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy: The Galectin-3 signature in NSCLCs [PDF]
, 2019 Checkpoint inhibitor-based immunotherapy is opening a promising scenario in oncology, with objective responses registered in multiple cancer types. However, reliable predictive markers of tumor responsiveness are still lacking.
Bartolazzi A. +4 more
core +1 more source
Immune Checkpoint Blockade in Cancer Therapy [PDF]
Journal of Clinical Oncology, 2015 Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) have demonstrated promise in a variety of malignancies. Ipilimumab (CTLA-4) and pembrolizumab (PD-1) are approved by the US Food and Drug Administration for the treatment of ...
Michael A, Postow +2 more
openaire +2 more sources
Immune checkpoint blockade in lymphoid malignancies [PDF]
The FEBS Journal, 2016 Malignant cells may subvert and escape endogenous host immune surveillance by up‐regulation of immune inhibitory signals known as immune checkpoints. These checkpoints are important therapeutic targets, and antibodies that block checkpoint signaling have shown remarkable efficacy in some solid tumors as well as in some refractory hematologic ...
Gita, Thanarajasingam +2 more
openaire +2 more sources
Corticosteroids and immune checkpoint blockade
Aging, 2015 Novel immunotherapies acting through immune checkpoint blockade to stimulate the immune response have demonstrated promising outcomes in advanced malignancies [1]. As a result, novel cancer immunotherapy was named a scientific breakthrough of the year in 2013 by Science.
Le, Min +2 more
openaire +2 more sources
HDAC inhibition potentiates immunotherapy in triple negative breast cancer. [PDF]
, 2017 Triple-negative breast cancer (TNBC) represents a more aggressive and difficult subtype of breast cancer where responses to chemotherapy occur, but toxicity is significant and resistance often follows. Immunotherapy has shown promising results in various
Ali, Niwa +8 more
core +1 more source
Cancer therapeutic implications of microRNAs in the regulation of immune checkpoint blockade
ExRNA, 2019 Dampening of patients’ immune response to tumor-specific antigens is a major reason for tumor development and progression. Within tumor microenvironment, aberrant expression of immune checkpoints changes T lymphocyte activity, and induces immune ...
Yan Zhang +2 more
doaj +1 more source
Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma [PDF]
, 2015 Melanoma is the deadliest form of skin cancer and has an incidence that is rising faster than any other solid tumor. Metastatic melanoma treatment has considerably progressed in the past five years with the introduction of targeted therapy (BRAF and MEK ...
Amaria, Rodabe N. +5 more
core +1 more source
Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. [PDF]
, 2020 Although immunotherapies have achieved remarkable salutary effects among subgroups of advanced cancers, most patients do not respond. We comprehensively evaluated biomarkers associated with the "cancer-immunity cycle" in the pan-cancer setting in order ...
Dressman, Devin +13 more
core +1 more source
Frontiers in Immunology, 2017 Immune checkpoint inhibitors, which target coinhibitory T cell molecules to promote anticancer immune responses, are on the rise to become a new pillar of cancer therapy.
Carmen Stecher +7 more
doaj +1 more source
LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance
Frontiers in Oncology, 2022 Although PD-1 blockade therapy has been promising in cancer treatment, only 4% (pancreatic cancer) to 70% (melanoma) of patients have a positive response to this blockade therapy, which is one of its important disadvantages. Therefore, it is important to
Yiming Wei, Zhaoming Li
doaj +1 more source